## David S Perlin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3002554/publications.pdf Version: 2024-02-01



DAVID S DEDLIN

#	Article	IF	CITATIONS
1	Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. Journal of Clinical Investigation, 2022, 132, .	8.2	15
2	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine, 2022, 14, eabn6859.	12.4	31
3	Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018). Medical Mycology, 2021, 59, 422-430.	0.7	15
4	Genetically related micafungin-resistant <i>Candida parapsilosis</i> blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?. Journal of Antimicrobial Chemotherapy, 2021, 76, 418-422.	3.0	29
5	Clinical and microbiological features of candiduria in critically ill adult patients in Shiraz, Iran (2016–2018): deviations from international guidelines and fluconazole therapeutic failure. Medical Mycology, 2021, 59, 600-607.	0.7	4
6	A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations. Emerging Microbes and Infections, 2021, 10, 994-997.	6.5	15
7	Preliminary Structural Elucidation of β-(1,3)-glucan Synthase from Candida glabrata Using Cryo-Electron Tomography. Journal of Fungi (Basel, Switzerland), 2021, 7, 120.	3.5	16
8	Diagnosis, clinical characteristics, and outcomes of COVID-19 patients from a large healthcare system in northern New Jersey. Scientific Reports, 2021, 11, 4389.	3.3	11
9	DNA damage response of major fungal pathogen Candida glabrata offers clues to explain its genetic diversity. Current Genetics, 2021, 67, 439-445.	1.7	5
10	Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	16
11	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. JCI Insight, 2021, 6, .	5.0	29
12	Environmental Clonal Spread of Azole-Resistant Candida parapsilosis with Erg11-Y132F Mutation Causing a Large Candidemia Outbreak in a Brazilian Cancer Referral Center. Journal of Fungi (Basel,) Tj ETQq0 C	) 0 rgBJ /0	verløøk 10 Tf 5
13	Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?. Antimicrobial Agents and Chemotherapy, 2021, 65.	3.2	6
14	Candidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs. Journal of Fungi (Basel,) Tj ETQq0	0 0 <sub>3</sub> gBT /(	Overlock 10 Tf
15	A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women. Frontiers in Microbiology, 2021, 12, 655069.	3.5	18
16	Clonal Candidemia Outbreak by Candida parapsilosis Carrying Y132F in Turkey: Evolution of a Persisting Challenge. Frontiers in Cellular and Infection Microbiology, 2021, 11, 676177.	3.9	34
17	Multidrug-resistant <i>Trichosporon</i> species: underestimated fungal pathogens posing imminent threats in clinical settings. Critical Reviews in Microbiology, 2021, 47, 679-698.	6.1	13
18	Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients. Frontiers in Medicine, 2021, 8, 649675.	2.6	18

#	Article	IF	CITATIONS
19	Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release (EVâ€CATCHER): A customizable purification assay designed for smallâ€RNA biomarker identification and evaluation of circulating smallâ€EVs. Journal of Extracellular Vesicles, 2021, 10, e12110.	12.2	26
20	Critical Assessment of Cell Wall Integrity Factors Contributing to in vivo Echinocandin Tolerance and Resistance in Candida glabrata. Frontiers in Microbiology, 2021, 12, 702779.	3.5	15
21	Antifungal Drug Susceptibility and Genetic Characterization of Fungi Recovered from COVID-19 Patients. Journal of Fungi (Basel, Switzerland), 2021, 7, 552.	3.5	6
22	Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-Resistant <i>Staphylococcus aureus</i> . ACS Infectious Diseases, 2021, 7, 2508-2521.	3.8	8
23	Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. PLoS Pathogens, 2021, 17, e1010025.	4.7	5
24	Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 70, 723-730.	5.8	73
25	Recent Increase in the Prevalence of Fluconazole-Non-susceptible Candida tropicalis Blood Isolates in Turkey: Clinical Implication of Azole-Non-susceptible and Fluconazole Tolerant Phenotypes and Genotyping. Frontiers in Microbiology, 2020, 11, 587278.	3.5	21
26	Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation. Biosensors and Bioelectronics, 2020, 169, 112572.	10.1	52
27	COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. Journal of Fungi (Basel, Switzerland), 2020, 6, 211.	3.5	170
28	First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	57
29	A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens. ACS Infectious Diseases, 2020, 6, 2431-2440.	3.8	15
30	Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS. MSphere, 2020, 5, .	2.9	33
31	The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens. Journal of Fungi (Basel, Switzerland), 2020, 6, 138.	3.5	84
32	Differential Regulation of Echinocandin Targets Fks1 and Fks2 in Candida glabrata by the Post-Transcriptional Regulator Ssd1. Journal of Fungi (Basel, Switzerland), 2020, 6, 143.	3.5	11
33	Efficacy of LAMB against Emerging Azole- and Multidrug-Resistant Candida parapsilosis Isolates in the Galleria mellonella Model. Journal of Fungi (Basel, Switzerland), 2020, 6, 377.	3.5	14
34	Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium. Antibiotics, 2020, 9, 877.	3.7	125
35	Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
36	Low level of antifungal resistance of <i>Candida glabrata</i> blood isolates in Turkey: Fluconazole minimum inhibitory concentration and <i>FKS</i> mutations can predict therapeutic failure. Mycoses, 2020, 63, 911-920.	4.0	34

#	Article	IF	CITATIONS
37	A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA. Cell Chemical Biology, 2020, 27, 560-570.e10.	5.2	20
38	COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment. Journal of Fungi (Basel, Switzerland), 2020, 6, 91.	3.5	292
39	Performance Evaluation of Culture-Independent SYBR Green Candida auris Quantitative PCR Diagnostics on Anterior Nares Surveillance Swabs. Journal of Clinical Microbiology, 2020, 58, .	3.9	6
40	A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method. Journal of Antimicrobial Chemotherapy, 2020, 75, 1799-1806.	3.0	10
41	A Noncanonical DNA Damage Checkpoint Response in a Major Fungal Pathogen. MBio, 2020, 11, .	4.1	14
42	Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies. Journal of Fungi (Basel, Switzerland), 2020, 6, 20.	3.5	9
43	Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. Journal of Fungi (Basel, Switzerland), 2020, 6, 192.	3.5	25
44	Membrane-Disrupting Nanofibrous Peptide Hydrogels. ACS Biomaterials Science and Engineering, 2019, 5, 4657-4670.	5.2	38
45	Identification of Drug Resistant Candida auris. Frontiers in Microbiology, 2019, 10, 1918.	3.5	80
46	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species. Journal of Antimicrobial Chemotherapy, 2019, 74, 2247-2254.	3.0	8
47	Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against <em>Candida albicans</em> and <em>Candida dubliniensis</em> . Infection and Drug Resistance, 2019, Volume 12, 1805-1814.	2.7	4
48	Novel <i>FKS1</i> and <i>FKS2</i> modifications in a high-level echinocandin resistant clinical isolate of <i>Candida glabrata</i> . Emerging Microbes and Infections, 2019, 8, 1619-1625.	6.5	29
49	Molecular Diagnostics in the Times of Surveillance for Candida auris. Journal of Fungi (Basel,) Tj ETQq1 1 0.7843	314 rgBT /0	Overlock 10 19
50	Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)- <scp>d</scp> -Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus. MBio, 2019, 10, .	4.1	48
51	Antifungal Consideration for Transplant Recipients. , 2019, , 927-940.		Ο
52	Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. Journal of Infectious Diseases, 2019, 220, 666-676.	4.0	51
53	Adipose Tissue Regulates Pulmonary Pathology during TB Infection. MBio, 2019, 10, .	4.1	27
54	Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16

#	Article	IF	CITATIONS
55	Beyond tissue concentrations: antifungal penetration at the site of infection. Medical Mycology, 2019, 57, S161-S167.	0.7	9
56	A Novel, Drug Resistance-Independent, Fluorescence-Based Approach To Measure Mutation Rates in Microbial Pathogens. MBio, 2019, 10, .	4.1	18
57	Echinocandin Resistance in <i>Aspergillus fumigatus</i> Has Broad Implications for Membrane Lipid Perturbations That Influence Drug-Target Interactions. Microbiology Insights, 2019, 12, 117863611989703.	2.0	9
58	Cell Wall-Modifying Antifungal Drugs. Current Topics in Microbiology and Immunology, 2019, 425, 255-275.	1.1	10
59	Detection of Candida auris Antifungal Drug Resistance Markers Directly from Clinical Skin Swabs. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
60	Rapid Detection of ERG11 -Associated Azole Resistance and FKS -Associated Echinocandin Resistance in Candida auris. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	49
61	Spontaneous Mutational Frequency and <i>FKS</i> Mutation Rates Vary by Echinocandin Agent against <i>Candida glabrata</i> . Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
62	Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients. Medical Mycology, 2019, 57, 38-44.	0.7	8
63	A novel, tomographic imaging probe for rapid diagnosis of fungal keratitis. Medical Mycology, 2018, 56, 796-802.	0.7	12
64	Absence of Azole or Echinocandin Resistance in Candida glabrata Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	47
65	Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	165
66	Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nature Microbiology, 2018, 3, 415-422.	13.3	338
67	<i>FKS2</i> and <i>FKS3</i> Genes of Opportunistic Human Pathogen Candida albicans Influence Echinocandin Susceptibility. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	33
68	An Optimized Synthetic-Bioinformatic Natural Product Antibiotic Sterilizes Multidrug-Resistant Acinetobacter baumannii-Infected Wounds. MSphere, 2018, 3, .	2.9	19
69	Comparative study of Candida spp. isolates: Identification and echinocandin susceptibility in isolates obtained from blood cultures in 15 hospitals in MedellÃn, Colombia. Journal of Global Antimicrobial Resistance, 2018, 13, 254-260.	2.2	12
70	A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 891-899.	3.0	380
71	2385. Ceftazidime–Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . Open Forum Infectious Diseases, 2018, 5, S711-S711.	0.9	1
72	A Novel, Rapid, and Low-Volume Assay for Therapeutic Drug Monitoring of Posaconazole and Other Long-Chain Azole-Class Antifungal Drugs. MSphere, 2018, 3, .	2.9	6

#	Article	IF	CITATIONS
73	Direct Detection of Emergent Fungal Pathogen Candida auris in Clinical Skin Swabs by SYBR Green-Based Quantitative PCR Assay. Journal of Clinical Microbiology, 2018, 56, .	3.9	63
74	Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Survival and Infection Burden in Vivo. Journal of Medicinal Chemistry, 2018, 61, 8337-8352.	6.4	35
75	VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice. Journal of Antimicrobial Chemotherapy, 2018, 73, 2089-2094.	3.0	23
76	Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	13
77	Significantly Improved Pharmacokinetics Enhances <i>In Vivo</i> Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	32
78	Multilocus Sequence Typing (MLST) Genotypes of Candida glabrata Bloodstream Isolates in Korea: Association With Antifungal Resistance, Mutations in Mismatch Repair Gene (Msh2), and Clinical Outcomes. Frontiers in Microbiology, 2018, 9, 1523.	3.5	38
79	Limited <i>ERG11</i> Mutations Identified in Isolates of Candida auris Directly Contribute to Reduced Azole Susceptibility. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	125
80	Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata. Journal of Fungi (Basel, Switzerland), 2018, 4, 105.	3.5	98
81	Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of <i>FKS</i> Genes and Cell Wall Remodeling. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	64
82	Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris. Journal of Clinical Microbiology, 2017, 55, 2445-2452.	3.9	140
83	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999–2015. Clinical Infectious Diseases, 2017, 65, 216-225.	5.8	50
84	The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	38
85	Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification. Journal of Infectious Diseases, 2017, 216, S458-S465.	4.0	40
86	Emergence of Echinocandin Resistance Due to a Point Mutation in the <i>fks1</i> Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	55
87	Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata. Scientific Reports, 2017, 7, 9099.	3.3	47
88	Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	73
89	The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infectious Diseases, The, 2017, 17, e383-e392.	9.1	670
90	<i>De Novo</i> Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	57

#	Article	IF	CITATIONS
91	A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment 1 1MPS is an investor in and consultant for Urogen. SAP is consultant and advisor for Vaccinex. The remaining authors have nothing to disclose Urologic Oncology: Seminars and Original Investigations, 2017, 35, 14-20.	1.6	67
	Meropenem-Vaborbactam vs. Piperacillin-Tazobactam in TANGO I (a Phase 3 Randomized, Double-blind) Tj ETQ		
92	Pyelonephritis. Open Forum Infectious Diseases, 2017, 4, S536-S536.	0.9	1
93	Echinocandin-resistant Candida tropicalis Bloodstream Infections. Open Forum Infectious Diseases, 2017, 4, S284-S285.	0.9	Ο
94	Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model. Open Forum Infectious Diseases, 2017, 4, S479-S479.	0.9	0
95	Expression Dynamics of Innate Immunity in Influenza Virus-Infected Swine. Frontiers in Veterinary Science, 2017, 4, 48.	2.2	2
96	The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Candida glabrata Colonization Mouse Model. Open Forum Infectious Diseases, 2017, 4, S129-S129.	0.9	0
97	An Aptamer-Based Biosensor for the Azole Class of Antifungal Drugs. MSphere, 2017, 2, .	2.9	18
98	Cryptococcus flips its lid - membrane phospholipid asymmetry modulates antifungal drug resistance and virulence. Microbial Cell, 2016, 3, 358-360.	3.2	7
99	Direct Molecular Diagnosis of Aspergillosis and CYP51A Profiling from Respiratory Samples of French Patients. Frontiers in Microbiology, 2016, 7, 1164.	3.5	21
100	Genetic Drivers of Multidrug Resistance in Candida glabrata. Frontiers in Microbiology, 2016, 7, 1995.	3.5	77
101	Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance. Frontiers in Microbiology, 2016, 7, 2038.	3.5	59
102	Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in Cryptococcus neoformans. MBio, 2016, 7, .	4.1	60
103	CD101: a novel longâ€acting echinocandin. Cellular Microbiology, 2016, 18, 1308-1316.	2.1	66
104	Rapid Detection of <i>FKS</i> -Associated Echinocandin Resistance in Candida glabrata. Antimicrobial Agents and Chemotherapy, 2016, 60, 6573-6577.	3.2	53
105	Biosynthesis of cell wall mannan in the conidium and the mycelium of <i>Aspergillusfumigatus</i> . Cellular Microbiology, 2016, 18, 1881-1891.	2.1	46
106	Discovery of MRSA active antibiotics using primary sequence from the human microbiome. Nature Chemical Biology, 2016, 12, 1004-1006.	8.0	149
107	Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nature Communications, 2016, 7, 11128.	12.8	227
108	Blood <i>Aspergillus</i> RNA is a promising alternative biomarker for invasive aspergillosis. Medical Mycology, 2016, 54, 801-807.	0.7	9

#	Article	IF	CITATIONS
109	Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae. Antimicrobial Agents and Chemotherapy, 2016, 60, 1226-1233.	3.2	7
110	Welcome Message from the Editor-in-Chief. Journal of Fungi (Basel, Switzerland), 2015, 1, 1-3.	3.5	0
111	Update on Antifungal Drug Resistance. Current Clinical Microbiology Reports, 2015, 2, 84-95.	3.4	130
112	Mechanisms of echinocandin antifungal drug resistance. Annals of the New York Academy of Sciences, 2015, 1354, 1-11.	3.8	214
113	Echinocandin Resistance in Candida. Clinical Infectious Diseases, 2015, 61, S612-S617.	5.8	248
114	Coping with Stress and the Emergence of Multidrug Resistance in Fungi. PLoS Pathogens, 2015, 11, e1004668.	4.7	52
115	Quick Detection of <i>FKS1</i> Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans. Journal of Clinical Microbiology, 2015, 53, 2037-2041.	3.9	16
116	Methylprednisolone impairs conidial phagocytosis but does not attenuate hyphal damage by neutrophils against Exserohilum rostratum. Medical Mycology, 2015, 53, 189-193.	0.7	6
117	Cross-Species Infectivity of H3N8 Influenza Virus in an Experimental Infection in Swine. Journal of Virology, 2015, 89, 11190-11202.	3.4	24
118	Mechanisms of Antifungal Drug Resistance. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a019752.	6.2	419
119	Dose escalation studies with caspofungin against Candida glabrata. Journal of Medical Microbiology, 2015, 64, 998-1007.	1.8	12
120	Target Enzyme Mutations Confer Differential Echinocandin Susceptibilities in Candida kefyr. Antimicrobial Agents and Chemotherapy, 2014, 58, 5421-5427.	3.2	13
121	Reply to "Detection of Multiple Fungal Species in Blood Samples by Real-Time PCR: an Interpretative Challenge― Journal of Clinical Microbiology, 2014, 52, 3517-3517.	3.9	0
122	Reply to "Not Over Yet: Fungal Infections following Methyl Prednisolone Injections Smoulder On― Journal of Clinical Microbiology, 2014, 52, 3508-3508.	3.9	0
123	Doripenem, Gentamicin, and Colistin, Alone and in Combinations, against Gentamicin-Susceptible, KPC-Producing Klebsiella pneumoniae Strains with Various <i>ompK36</i> Genotypes. Antimicrobial Agents and Chemotherapy, 2014, 58, 3521-3525.	3.2	34
124	Clostridium difficile infection in Brazil: A neglected problem?. American Journal of Infection Control, 2014, 42, 459-460.	2.3	16
125	Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management. Drugs, 2014, 74, 1573-1585.	10.9	82
126	Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints. International Journal of Antimicrobial Agents, 2014, 44, 248-255.	2.5	20

#	Article	IF	CITATIONS
127	Set of Classical PCRs for Detection of Mutations in <i>Candida glabrata FKS</i> Genes Linked with Echinocandin Resistance. Journal of Clinical Microbiology, 2014, 52, 2609-2614.	3.9	44
128	Methylprednisolone Enhances the Growth of Exserohilum rostratum In Vitro, Attenuates Spontaneous Apoptosis, and Increases Mortality Rates in Immunocompetent Drosophila Flies. Journal of Infectious Diseases, 2014, 210, 1471-1475.	4.0	10
129	Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin. Antimicrobial Agents and Chemotherapy, 2014, 58, 2438-2440.	3.2	61
130	Host Biomarkers of Invasive Pulmonary Aspergillosis To Monitor Therapeutic Response. Antimicrobial Agents and Chemotherapy, 2014, 58, 3373-3378.	3.2	18
131	Fungal DNA Detected in Blood Samples of Patients Who Received Contaminated Methylprednisolone Injections Reveals Increased Complexity of Causative Agents. Journal of Clinical Microbiology, 2014, 52, 2212-2215.	3.9	10
132	Current perspectives on echinocandin class drugs. Future Microbiology, 2011, 6, 441-457.	2.0	215
133	Echinocandin-Resistant Candida: Molecular Methods and Phenotypes. Current Fungal Infection Reports, 2011, 5, 113-119.	2.6	19
134	Molecular diagnostic platforms for detecting <i>Aspergillus</i> . Medical Mycology, 2009, 47, S223-S232.	0.7	26
135	Antifungal drug resistance: do molecular methods provide a way forward?. Current Opinion in Infectious Diseases, 2009, 22, 568-573.	3.1	82
136	Multiplex Detection of Mutations. Methods in Molecular Biology, 2008, 429, 23-31.	0.9	3
137	Resistance to echinocandin-class antifungal drugs. Drug Resistance Updates, 2007, 10, 121-130.	14.4	440
138	Role of α(1-3)-glucan in <i>Aspergillus fumigatus</i> and other human fungal pathogens. , 2007, , 269-288.		5
139	Caspofungin Uptake Is Mediated by a High-Affinity Transporter in Candida albicans. Antimicrobial Agents and Chemotherapy, 2004, 48, 3845-3849.	3.2	46
140	Amphotericin B cochleates: a vehicle for oral delivery. Current Opinion in Investigational Drugs, 2004, 5, 198-201.	2.3	8
141	Cross-Resistance of Clinical Isolates ofCandida albicansandCandida glabratato Over-the-Counter Azoles Used in the Treatment of Vaginitis. Microbial Drug Resistance, 2000, 6, 155-161.	2.0	53
142	Cochleates: New Lipid-Based Drug Delivery System. Journal of Liposome Research, 2000, 10, 523-538.	3.3	72
143	Fungal Plasma Membrane Proton Pumps as Promising New Antifungal Targets. Critical Reviews in Microbiology, 1994, 20, 209-223.	6.1	86

144 Antifungal Mechanisms of Action and Resistance. , 0, , 457-466.

1